

Diabetic Cardiomyopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/D9E526E2763CEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: D9E526E2763CEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Diabetic Cardiomyopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Diabetic Cardiomyopathy Understanding

Diabetic Cardiomyopathy: Overview

Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition,

and cardiac fibrosis.

“Diabetic Cardiomyopathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.

Diabetic Cardiomyopathy Emerging Drugs Chapters

This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Cardiomyopathy Emerging Drugs

IMB-1018972: Imbria Pharmaceuticals

Mechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiomyopathy

AT-001: Applied Therapeutics

AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied

Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.

Further product details are provided in the report.....

Diabetic Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Cardiomyopathy

There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

- Late-stage products (Phase III)

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.

Diabetic Cardiomyopathy Report Insights

Diabetic Cardiomyopathy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Diabetic Cardiomyopathy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diabetic Cardiomyopathy drugs?

How many Diabetic Cardiomyopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diabetic Cardiomyopathy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Imbria Pharmaceuticals

Applied Therapeutics

Key Products

IMB-1018972

AT-001

Contents

Introduction

Executive Summary

Diabetic Cardiomyopathy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Diabetic Cardiomyopathy – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Diabetic Cardiomyopathy companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Diabetic Cardiomyopathy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

AT-001: Applied Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

IMB-101897: Imbria Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Diabetic Cardiomyopathy Key Companies

Diabetic Cardiomyopathy Key Products

Diabetic Cardiomyopathy- Unmet Needs

Diabetic Cardiomyopathy- Market Drivers and Barriers

Diabetic Cardiomyopathy- Future Perspectives and Conclusion

Diabetic Cardiomyopathy Analyst Views

Diabetic Cardiomyopathy Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Diabetic Cardiomyopathy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Diabetic Cardiomyopathy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Diabetic Cardiomyopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/D9E526E2763CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D9E526E2763CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970